

Amendments to Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-92. (Canceled).

93. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate; wherein the immunoconjugate comprises at least one maytansinoid compound linked to a monoclonal antibody or fragment thereof; and wherein the monoclonal antibody or fragment thereof binds to an antigen expressed by a cancer cell.

94. (Previously presented) The pharmaceutical composition of claim 93, wherein the chemotherapeutic agent is a taxane compound, an epothilone compound, a platinum compound, an epipodophyllotoxin compound, a camptothecin compound, or a mixture of two or more thereof.

95. (Previously presented) The pharmaceutical composition of claim 93, wherein the chemotherapeutic agent is a taxane compound, a platinum compound, an epipodophyllotoxin compound, a camptothecin compound, or a mixture of two or more thereof.

96. (Previously presented) The pharmaceutical composition of claim 93, wherein the chemotherapeutic agent is paclitaxel, docetaxel, epothilone A, epothilone B, epothilone C, epothilone D, epothilone E, epothilone F, cisplatin, carboplatin, oxaliplatin, iproplatin, ormaplatin, tetraplatin, etoposide, teniposide, camptothecin, topotecan, irinotecan, 9-aminocamptothecin, or a mixture of two or more thereof.

97. (Previously presented) The pharmaceutical composition of claim 93, wherein the chemotherapeutic agent is paclitaxel, cisplatin, etoposide, docetaxel, topotecan, or a mixture of two or more thereof.


98. (Previously presented) The pharmaceutical composition of claim 93, wherein the monoclonal antibody or fragment thereof binds to a CD56 antigen.

99. (Previously presented) The pharmaceutical composition of claim 93, wherein the monoclonal antibody or fragment thereof is at least one of Fv, Fab, Fab' or F(ab')₂.

100. (Previously presented) The pharmaceutical composition of claim 93, wherein the monoclonal antibody or fragment thereof is humanized N901.

101. (Previously presented) The pharmaceutical composition of claim 93, wherein the monoclonal antibody or fragment thereof is humanized C242.


102. (Previously presented) The pharmaceutical composition of claim 93, wherein the immunoconjugate comprises at least one maytansinoid compound of formula (IV):



wherein Z_0 is H or SR; R is methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic; t is 1, 2 or 3; Y_0 is chlorine or hydrogen; and X_3 is hydrogen or methyl.


103. (Previously presented) The pharmaceutical composition of claim 102, wherein Z_0 is H; t is 2; Y_0 is chlorine; and X_3 is methyl.

104. (Previously presented) The pharmaceutical composition of claim 93, wherein the immunoconjugate is of the formula:



wherein MAb is a monoclonal antibody or fragment thereof that binds to an antigen expressed by the cancer cell.

105. (Previously presented) A pharmaceutical composition comprising a synergistic combination of at least one chemotherapeutic agent and at least one immunoconjugate; wherein the chemotherapeutic agent is a taxane compound, an epothilone compound, a platinum compound, an epipodophyllotoxin compound, a camptothecin compound, or a mixture of two or more thereof; and wherein the immunoconjugate is:



wherein MAb is a monoclonal antibody or fragment thereof that binds to an antigen expressed by a cancer cell.

106. (Previously presented) A kit comprising a therapeutically effective amount of at least one chemotherapeutic agent and a therapeutically effective amount of at least one immunoconjugate; wherein the immunoconjugate comprises at least one maytansinoid compound linked to a monoclonal antibody or fragment thereof; and wherein the monoclonal antibody or fragment thereof binds to an antigen expressed by a cancer cell.

107. (Previously presented) The kit of claim 106, wherein the chemotherapeutic agent is a taxane compound, an epothilone compound, a platinum compound, an epipodophyllotoxin compound, a camptothecin compound, or a mixture of two or more thereof.

108. (Previously presented) The kit of claim 106, wherein the chemotherapeutic agent is a taxane compound, a platinum compound, an epipodophyllotoxin compound, a camptothecin compound, or a mixture of two or more thereof.

109. (Previously presented) The kit of claim 106, wherein the chemotherapeutic agent is paclitaxel, docetaxel, epothilone A, epothilone B, epothilone C, epothilone D, epothilone E, epothilone F, cisplatin, carboplatin, oxaliplatin, iproplatin, ormaplatin, tetraplatin, etoposide, teniposide, camptothecin, topotecan, irinotecan, 9-aminocamptothecin, or a mixture of two or more thereof.

110. (Previously presented) The kit of claim 106, wherein the chemotherapeutic agent is paclitaxel, cisplatin, etoposide, docetaxel, topotecan, or a mixture of two or more thereof.


111. (Previously presented) The kit of claim 106, wherein the monoclonal antibody or fragment thereof binds to a CD56 antigen.

112. (Previously presented) The kit of claim 106, wherein the monoclonal antibody or fragment thereof is at least one of Fv, Fab, Fab' or F(ab')₂.

113. (Previously presented) The kit of claim 106, wherein the monoclonal antibody or fragment thereof is humanized N901.

114. (Previously presented) The kit of claim 106, wherein the monoclonal antibody or fragment thereof is humanized C242.

115. (Previously presented) The kit of claim 106, wherein the immunoconjugate comprises at least one maytansinoid compound of formula (IV):




(IV)

wherein Z₀ is H or SR; R is methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic; t is 1, 2 or 3; Y₀ is chlorine or hydrogen; and X₃ is hydrogen or methyl.

116. (Previously presented) The kit of claim 115, wherein Z₀ is H; t is 2; Y₀ is chlorine; and X₃ is methyl.

117. (Previously presented) The kit of claim 106, wherein the immunoconjugate is:




wherein MAb is a monoclonal antibody or fragment thereof that binds to an antigen expressed by the cancer cell.

118. (Previously presented) The kit of claim 106, wherein the immunoconjugate and chemotherapeutic agent are separate components in the kit.

119. (Previously presented) The kit of claim 106, wherein the immunoconjugate and chemotherapeutic agent are in the form of a composition in the kit.

120. (Currently amended) A kit comprising a synergistic combination of at least one chemotherapeutic agent selected from the group consisting of a taxane compound, an epothilone compound, a platinum compound, an epipodophyllotoxin compound, a camptothecin compound, or a mixture of two or more thereof; and at least one immunoconjugate represented by:




wherein MAb is a monoclonal antibody or fragment thereof that binds to an antigen expressed by the a cancer cell.

121-143. (Canceled)

144. (New) A pharmaceutical composition comprising a therapeutically effective amount of (i) at least one chemotherapeutic agent selected from the group consisting of paclitaxel, docetaxel, cisplatin, etoposide, topotecan and irinotecan and (ii) an immunoconjugate comprising a maytansinoid and a humanized monoclonal antibody selected from the group consisting of N901 and C242.


145. (New) The pharmaceutical composition of claim 144, wherein the maytansinoid is a compound of formula (IV):



wherein Z_0 is H or SR; wherein R is methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic; t is 1, 2 or 3; Y_0 is chlorine or hydrogen; and X_3 is hydrogen or methyl.

146. (New) A kit comprising a therapeutically effective amount of (i) at least one chemotherapeutic agent selected from the group consisting of paclitaxael, docetaxel, cisplatin, etoposide, topotecan and irinotecan and (ii) an immunoconjugate comprising a maytansinoid and a humanized monoclonal antibody selected from the group consisting of N901 and C242.


147. (New) The kit of claim 146, wherein the maytansinoid is a compound of formula (IV):



wherein Z_0 is H or SR; wherein R is methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic; t is 1, 2 or 3; Y_0 is chlorine or hydrogen; and X_3 is hydrogen or methyl.

148. (New) A pharmaceutical composition comprising a therapeutically effective amount of (i) at least one chemotherapeutic agent selected from the group consisting of paclitaxel, docetaxel, cisplatin, etoposide, topotecan and irinotecan and (ii) an immunoconjugate comprising a maytansinoid and a humanized monoclonal antibody or fragment thereof that binds to an antigen expressed by a small cell lung cancer cell, a non small cell lung cancer cell or a colorectal cancer cell.


149. (New) The pharmaceutical composition of claim 148, wherein the maytansinoid is a compound of formula (IV):



wherein Z_0 is H or SR; wherein R is methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic; t is 1, 2 or 3; Y_0 is chlorine or hydrogen; and X_3 is hydrogen or methyl.

150. (New) A kit comprising a therapeutically effective amount of (i) at least one chemotherapeutic agent selected from the group consisting of paclitaxel, docetaxel, cisplatin, etoposide, topotecan and irinotecan and (ii) an immunoconjugate comprising a maytansinoid and a humanized monoclonal antibody or fragment thereof that binds to an antigen expressed by a small cell lung cancer cell, a non small cell lung cancer cell or a colorectal cancer cell.

151. (New) The kit of claim 150, wherein the maytansinoid is a compound of formula (IV):



(IV)

wherein Z_0 is H or SR; wherein R is methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic; t is 1, 2 or 3; Y_0 is chlorine or hydrogen; and X_3 is hydrogen or methyl.